Description
Amoglimy MV2 is a triple-combination oral antidiabetic medication containing Glimepiride 2 mg, Voglibose 0.2 mg, and Metformin Hydrochloride 500 mg, formulated for the effective management of Type 2 diabetes mellitus. Glimepiride stimulates the pancreas to release insulin, Metformin improves insulin sensitivity and reduces glucose production in the liver, while Voglibose delays the absorption of carbohydrates from the intestine, helping control post-meal blood glucose spikes. This comprehensive formulation provides effective glycemic control and supports long-term diabetes management when combined with a healthy diet, regular exercise, and lifestyle modifications. For safe and effective use, Amoglimy MV2 should be taken strictly as advised by your doctor or healthcare professional.
